Grant: Project Grant
University of Calgary
$100,000.00
Acute Clot Thrombolysis: Late-window Administration of Tenecteplase in Extended Acute Ischemic Stroke (ACT-LATE).
FY 2026-27
Summary
Stroke is one of the leading causes of death and disability in Canada. For patients who present with symptoms within 4.5 hours of onset, intravenous thrombolysis, a clot busting medication, can dissolve the clot and restore cerebral blood flow. In some patients the clot can also be physically removed with a procedure called endovascular thrombectomy. However, this procedure can only be performed in highly specialised centres and access for patients living in many parts of Canada is often significantly delayed. Patients who present between 4.5 and 24 hours after stroke onset and also lack access to thrombectomy represent a large and underserved population. Currently, there is no established treatment pathway for
these individuals, and outcomes remain poor. This study aims to evaluate the safety and efficacy of intravenous thrombolysis in patients presenting between 4.5 and 24 hours after
stroke onset who are ineligible for or unable to access thrombectomy. Participants will be randomly chosen to either receive a clot busting medicine or standard care. We will follow these patients for 90 days, focusing on functional recovery and neurological improvement. If successful, this trial could redefine stroke care for late-presenting patients, offering a scalable
solution. The findings have the potential to inform national and international guidelines and improve equity and outcomes in stroke management.
Department
Program
Project Grant
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
575412
Name
Coutts Shelagh B
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Randomized Controlled Trials 2
Projecttitle
Acute Clot Thrombolysis: Late-window Administration of Tenecteplase in Extended Acute Ischemic Stroke (ACT-LATE).
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Clinical Trial; Stroke
Abstract
Stroke is one of the leading causes of death and disability in Canada. For patients who present with symptoms within 4.5 hours of onset, intravenous thrombolysis, a clot busting medication, can dissolve the clot and restore cerebral blood flow. In some patients the clot can also be physically removed with a procedure called endovascular thrombectomy. However, this procedure can only be performed in highly specialised centres and access for patients living in many parts of Canada is often significantly delayed. Patients who present between 4.5 and 24 hours after stroke onset and also lack access to thrombectomy represent a large and underserved population. Currently, there is no established treatment pathway for
these individuals, and outcomes remain poor. This study aims to evaluate the safety and efficacy of intravenous thrombolysis in patients presenting between 4.5 and 24 hours after
stroke onset who are ineligible for or unable to access thrombectomy. Participants will be randomly chosen to either receive a clot busting medicine or standard care. We will follow these patients for 90 days, focusing on functional recovery and neurological improvement. If successful, this trial could redefine stroke care for late-presenting patients, offering a scalable
solution. The findings have the potential to inform national and international guidelines and improve equity and outcomes in stroke management.
Competitiondate
202604
Approvedterm2
1 yr 0 mth
Pinamesdelim
Coutts, Shelagh B; Yogendrakumar, Vignan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~